📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
79 announcements match the current filters (relevance ≥ 5).
Aurobindo's CuraTeQ Receives Brazil's ANVISA Approval for Biosimilars Facility
Aurobindo Pharma's wholly owned subsidiary, CuraTeQ Biologics, has received GMP approval from Brazil's ANVISA for its Hyderabad-based biosimilars manufacturing facility. The approval follows a successful inspection conducted from May 11 to May 15, 2026, covering four biosimilar products. This facility already holds EMA and WHO certifications, and this new clearance enables entry into the Brazilian and broader Latin American markets. This is a key milestone for the company's biosimilar portfolio, which is a central pillar of its long-term growth strategy.
Confidence: HIGH
What changedThe Hyderabad biosimilars facility has gained regulatory clearance to supply products to Brazil, expanding its authorized global footprint beyond Europe and WHO-regulated regions.
Why it mattersBiosimilars are a high-margin growth driver for Aurobindo; securing approvals in 'Growth Markets' like Brazil helps diversify revenue away from the price-sensitive US API and formulation markets.
Biosimilar products covered: 4Inspection period: May 11 to May 15, 2026Subsidiary ownership: 100%TTM Revenue: ₹33,653 Cr
📅 Short termThe news is likely to be viewed positively by the market as it validates the quality of the company's biologics infrastructure and clears a path for Latin American revenue.
📈 Long termThis supports Aurobindo's structural shift toward complex generics and biologics, which is essential for maintaining margins as traditional API pricing remains under pressure.
⚠ Risk flags
- Regulatory delays in USFDA inspections (expected late 2026) could still postpone major US revenue from this facility.
Key Highlights
Approval covers 4 biosimilar products across mammalian and microbial drug substance manufacturing platforms.
GMP inspection was successfully completed by ANVISA between May 11 and May 15, 2026.
Facility includes drug substance, prefillable syringe, vial filling, and QC testing laboratories.
CuraTeQ Biologics is a 100% subsidiary of Aurobindo Pharma, which has a TTM revenue of ₹33,653 Cr.
The facility is already EMA and WHO certified, confirming high global regulatory standards.
👀 What to Watch
Investors should monitor the commercialization timeline for biosimilars in the Latin American market and watch for the upcoming USFDA inspection of this facility expected in late 2026.
Aurobindo Pharma sets up Indonesian manufacturing unit with IDR 20 Billion capital
Aurobindo Pharma has incorporated a new wholly owned step-down subsidiary, PT Auro Pharm Indonesia, to establish manufacturing operations in Indonesia. The initial capital subscription is IDR 20,000,000,000 (approximately ₹10.5 Cr), representing 100% ownership. This move aligns with the company's stated strategy to expand in 'Growth Markets' including Indonesia, China, and Brazil. While the initial investment is small relative to the company's ₹33,653 Cr TTM revenue, it marks a transition from distribution to local manufacturing in the region.
Confidence: HIGH
What changedAurobindo has established a dedicated manufacturing subsidiary in Indonesia, moving beyond its existing presence to localized production.
Why it mattersLocal manufacturing in Indonesia, a designated growth market, helps the company bypass import barriers and improve supply chain efficiency in Southeast Asia.
Initial Capital: IDR 20,000,000,000Ownership Stake: 100%Approval Date: July 9, 2026TTM Revenue: ₹33,653 CrInvestment vs TTM Revenue: ~0.03%
📅 Short termThe market is likely to view this as a positive strategic step, though the immediate financial impact is negligible due to the small initial capital outlay.
📈 Long termThis is structurally significant as it builds the foundation for Aurobindo's manufacturing footprint in Growth Markets, supporting long-term revenue diversification.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in setting up a greenfield manufacturing facility in a foreign jurisdiction
- Regulatory compliance in the Indonesian pharmaceutical market
Key Highlights
Initial capital subscription of IDR 20,000,000,000 for 2,000 equity shares
100% ownership held through step-down subsidiary PT Aurogen Pharma Indonesia
Incorporation approved by Indonesian authorities on July 9, 2026
Entity specifically created to undertake manufacturing operations in Indonesia
Aligns with the company's goal to scale Growth Markets alongside its $1 billion Europe revenue target
👀 What to Watch
Watch for future capex announcements and the timeline for the commencement of manufacturing at this new Indonesian facility.
Aurobindo Pharma Completes Transfer of Domestic Branded Business to Subsidiary Auropharm
Aurobindo Pharma has finalized the transfer of its domestic branded generic pharmaceutical formulations business to its wholly-owned subsidiary, Auropharm Limited. The transfer was executed as a slump sale on a going concern basis, effective July 1, 2026. This move follows the initial Business Transfer Agreement (BTA) signed on April 6, 2026. While the transaction value was not disclosed in this filing, the restructuring consolidates the domestic branded portfolio into a dedicated legal entity.
Confidence: HIGH
What changedThe company's domestic branded generic business has been legally and operationally moved from the parent company to a dedicated 100% subsidiary, Auropharm Limited.
Why it mattersThis internal restructuring often precedes strategic actions such as bringing in private equity partners, a separate IPO, or simply improving operational focus on the domestic market vs. the larger export business (TTM Revenue Rs 33,653 Cr).
Effective Date: July 1, 2026Subsidiary Ownership: 100%TTM Revenue (Consolidated): Rs 33,653 CrTransaction Value: not disclosed
📅 Short termNeutral; as an internal transfer between a parent and a 100% subsidiary, there is no immediate impact on consolidated financials or shareholder value.
📈 Long termPotentially significant if this is a precursor to value unlocking in the domestic formulations segment, which typically commands higher margins than the API/Bulk drug business.
Key Highlights
Transfer of domestic branded generic formulations business completed effective July 1, 2026
Business moved to Auropharm Limited, a 100% wholly-owned subsidiary of Aurobindo Pharma
Transaction executed on a 'slump sale' basis as a going concern
Follows the initial regulatory intimation and BTA dated April 6, 2026
👀 What to Watch
Monitor future quarterly filings for the specific valuation of this slump sale and any strategic commentary regarding potential stake sales or separate listing of the domestic business entity.
Aurobindo Pharma Completes Acquisition of US-Based Lannett Company, Inc.
Aurobindo Pharma's US subsidiary, APUSA, has successfully completed the acquisition of Lannett Company, Inc. following U.S. Federal Trade Commission approval on June 18, 2026. Effective June 29, 2026, Lannett operates as a wholly owned subsidiary, Lannett Company LLC, adding over 400 employees to Aurobindo's workforce. This acquisition is a strategic move to strengthen the company's US market position and expand its product portfolio, supporting its TTM revenue base of Rs 33,653 Cr.
Confidence: HIGH
What changedAurobindo has transitioned from an agreement to full ownership of Lannett Company, Inc., making it an operational part of its US business.
Why it mattersThe US market is a critical revenue driver for Aurobindo; this acquisition provides immediate scale, a broader product portfolio, and additional talent to combat pricing pressures in the generic pharmaceutical space.
Completion Date: June 29, 2026FTC Approval Date: June 18, 2026Employees Added: 400+TTM Revenue: Rs 33,653 CrMarket Cap: Rs 91,259 Cr
📅 Short termThe completion of the acquisition removes regulatory uncertainty and is likely to be viewed positively by the market as the company begins consolidating Lannett's financials.
📈 Long termThis is a structural move to diversify the US portfolio and reach the company's long-term growth targets, helping to offset volatility in the API segment.
⚠ Risk flags
- Integration risks
- Potential for initial margin dilution
- Regulatory compliance of acquired assets
Key Highlights
Acquisition of Lannett Company, Inc. completed effective June 29, 2026
U.S. Federal Trade Commission (FTC) approval received on June 18, 2026
Integration of more than 400 Lannett employees into the APUSA organization
Lannett will operate as a wholly owned subsidiary under the name Lannett Company LLC
👀 What to Watch
Investors should monitor the integration timeline and the specific contribution of Lannett to US formulation margins in the next 2-3 quarters. Watch for updates on product synergies and any potential cost-saving measures from the combined operations.
Aurobindo Pharma Subsidiary Auroactive Pharma Completes US FDA Audit with 2 Observations
The US FDA conducted a five-day inspection at Auroactive Pharma Private Limited, a wholly owned subsidiary of Aurobindo Pharma, from June 22 to June 26, 2026. The facility, located in Srikakulam, Andhra Pradesh, is a key site for manufacturing Active Pharmaceutical Ingredients (API) and Pharmaceutical Formulation Intermediates. The audit concluded with 2 observations, which the company plans to address within the stipulated timeframe. Management has indicated that there is currently no quantifiable impact on the company's financial or operational activities.
Key Highlights
US FDA inspection conducted at the Srikakulam API facility from June 22 to June 26, 2026.
The audit concluded with 2 observations issued by the regulatory authority.
Facility manufactures both Active Pharmaceutical Ingredients (API) and Pharmaceutical Formulation Intermediates.
Company confirms no immediate impact on financial or operational performance due to these observations.
👀 What to Watch
Investors should maintain a neutral stance as 2 observations is a relatively low number for a major API facility. Monitor for the final classification of the inspection (EIR) to ensure no escalation to a Warning Letter or OAI status.
Aurobindo Pharma USA to Acquire Lannett Company for $250 Million Following FTC Approval
Aurobindo Pharma USA has received FTC approval to acquire Lannett Company LLC for $250 million on a cash-free, debt-free basis. The transaction is expected to close by the end of June 2026 and will be immediately accretive to Aurobindo Group’s earnings per share (EPS). The acquisition includes a manufacturing facility in Indiana with a 4-billion-dose annual capacity, significantly strengthening the company's U.S. domestic manufacturing footprint and its portfolio of complex, non-opioid controlled substances.
Key Highlights
Acquisition of Lannett Company LLC valued at $250 million on a cash-free, debt-free basis.
Received U.S. Federal Trade Commission (FTC) approval with closing expected by June 30, 2026.
Adds a manufacturing site in Seymour, Indiana, capable of producing 4 billion doses annually.
Expected to be immediately accretive to the Group's EPS with significant SG&A and operational synergies.
Expands product offering in the specialized segment of complex, non-opioid controlled substances.
👀 What to Watch
Investors should view this as a positive development as it enhances U.S. manufacturing capabilities and is expected to boost earnings immediately. Monitor the integration of the Indiana facility and the realization of cost synergies in future earnings calls.
US FDA Completes Inspection at Aurobindo's Eugia Steriles Facility with 5 Observations
The US FDA conducted a Pre-Approval Inspection (PAI) at Eugia Steriles Private Limited, a 100% stepdown subsidiary of Aurobindo Pharma, between June 10 and June 19, 2026. The inspection at the Andhra Pradesh facility concluded with 5 observations, which the company plans to address within the stipulated timeframe. While the company states there is no immediate impact on financials or operations, the outcome of these observations is critical for future product approvals from this site. Investors should monitor the final classification of the inspection by the US FDA.
Key Highlights
US FDA conducted a Pre-Approval Inspection (PAI) at the Eugia Steriles facility from June 10 to June 19, 2026.
The regulatory audit concluded with 5 observations issued to the subsidiary.
Eugia Steriles is a 100% stepdown subsidiary located in Anakapalli District, Andhra Pradesh.
Aurobindo Pharma has committed to responding to the observations within the required timeline.
The company currently reports no quantifiable impact on financial or operational activities.
👀 What to Watch
Investors should remain cautious and wait for the specific nature of the 5 observations to be disclosed or for the final EIR (Establishment Inspection Report). The stock may see some volatility as sterile facilities are subject to higher regulatory scrutiny and are vital for the company's injectable portfolio.
US FDA Concludes Inspection at Aurobindo's Eugia Steriles Unit with 5 Observations
Aurobindo Pharma's stepdown subsidiary, Eugia Steriles Private Limited, underwent a US FDA Pre-Approval Inspection (PAI) at its Andhra Pradesh facility from June 10 to June 19, 2026. The inspection concluded with 5 observations, which the company plans to address within the stipulated timeframe. While the company states there is no immediate impact on financials or operations, the resolution of these observations is critical for future product approvals from this site.
Key Highlights
US FDA conducted a Pre-Approval Inspection (PAI) at Eugia Steriles from June 10 to June 19, 2026.
The inspection resulted in 5 observations issued by the regulator.
The facility is a 100% stepdown subsidiary located in Anakapalli District, Andhra Pradesh.
Aurobindo Pharma has committed to responding to the observations within the required timeline.
Management indicates no immediate quantifiable impact on current financials or operations.
👀 What to Watch
Investors should monitor the severity of the 5 observations and the subsequent FDA classification, as these could delay new product launches from the Eugia facility. Maintain a watch on the company's remediation progress.
Aurobindo Pharma's Eugia Unit-III Classified as OAI by US FDA Following 11 Observations
The US FDA has classified the inspection of Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma Specialities Ltd (Unit-III), as 'Official Action Indicated' (OAI). This follows an inspection conducted from January 27 to February 06, 2026, which resulted in 11 observations. An OAI status is a significant regulatory setback as it typically means the FDA may withhold approvals for new drug applications from this facility until corrective actions are verified. Although the company claims no immediate financial impact, this status increases the risk of further regulatory escalations like Warning Letters.
Key Highlights
US FDA classifies Eugia Unit-III formulation facility as 'Official Action Indicated' (OAI).
The classification stems from an inspection conducted between January 27 and February 06, 2026.
The facility had previously received 11 observations during the conclusion of the inspection.
Eugia Unit-III is a key formulation manufacturing site for the company's specialty segment.
Company states there is no immediate quantifiable impact on current financials or operations.
👀 What to Watch
Investors should exercise caution as OAI status often leads to delays in Abbreviated New Drug Application (ANDA) approvals from the affected site. Monitor for any follow-up Warning Letters or Import Alerts which would have a more direct impact on existing revenue streams.
Aurobindo Pharma Gets US FDA Approval for Tofacitinib Tablets; Market Size $494 Million
Aurobindo Pharma has received final US FDA approval for Tofacitinib Tablets (5 mg and 10 mg), a generic version of Xeljanz. The product addresses a significant US market estimated at $494 million for the twelve months ending April 2026. The company intends to launch the product immediately through its wholly owned subsidiary, APL Healthcare Unit IV. This approval strengthens Aurobindo's US portfolio, which now includes 561 final ANDA approvals.
Key Highlights
Final US FDA approval received for Tofacitinib Tablets (5 mg and 10 mg) for arthritis and ulcerative colitis.
Estimated annual US market size for the product is approximately $494 million as of April 2026.
The product will be launched immediately from the APL Healthcare Unit IV manufacturing facility.
Aurobindo now possesses a total of 586 ANDA approvals, including 561 final and 25 tentative approvals.
👀 What to Watch
This approval is a positive catalyst for the company's US generics business in a high-value therapeutic segment. Investors should monitor the company's ability to capture market share from the reference drug Xeljanz.
Aurobindo Pharma Launches TheraNym Biologics CMO Facility with MSD as Anchor Customer
Aurobindo Pharma has inaugurated TheraNym, one of India's largest dedicated biologics contract manufacturing organizations (CMO), located in Telangana. The facility is equipped with 15 KL bioreactors and advanced fill-finish capabilities designed for global regulatory standards. Significantly, global pharmaceutical giant MSD has joined as the anchor customer, providing immediate validation and revenue visibility for the new venture. This strategic move marks Aurobindo's entry into the high-growth, high-margin biologics CDMO segment, diversifying its portfolio beyond traditional generics.
Key Highlights
Inaugurated TheraNym, a large-scale biologics contract manufacturing facility in Borapatla, Telangana.
Secured global leader MSD as the anchor customer to support their domestic and export supply chains.
Facility features 15 KL bioreactors, advanced downstream processing, and aseptic fill-finish capabilities.
Strategic expansion into the biologics CMO market to capture global demand for biologic therapies.
Leverages India's PLI scheme and Telangana's Life Sciences ecosystem for competitive manufacturing.
👀 What to Watch
Investors should monitor the facility's ramp-up and the potential for additional high-profile client acquisitions beyond MSD. This expansion into biologics CDMO is a significant long-term growth lever that could improve the company's margin profile and reduce generic pricing pressure risks.
Aurobindo Pharma's Subsidiary Eugia Unit-I Classified as OAI by US FDA
The US FDA has classified Unit-I of Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, as Official Action Indicated (OAI). This follows an inspection conducted in February 2026 which resulted in 4 observations at the formulation manufacturing facility in Telangana. An OAI status indicates that the FDA may withhold approvals for new drug applications from this site until corrective actions are verified. While the company claims no immediate financial impact, this regulatory setback could delay the launch of new products from this specific unit.
Key Highlights
US FDA classifies Eugia Pharma Unit-I as Official Action Indicated (OAI) following a February 2026 inspection.
The inspection of the formulation manufacturing facility concluded with 4 observations.
OAI status typically leads to the withholding of new product approvals from the affected facility.
The company maintains that there is no immediate quantifiable impact on current financials or operations.
Unit-I is a wholly owned subsidiary located in Shameerpet, Telangana.
👀 What to Watch
Investors should exercise caution as OAI status increases the risk of a Warning Letter or Import Alert if remediation is unsatisfactory. Monitor management commentary regarding the timeline for resolving these FDA observations to clear the path for future product launches.
Aurobindo Pharma Incorporates New French Subsidiary for Generic Manufacturing with €100,000 Capital
Aurobindo Pharma, through its step-down subsidiary Agile Pharma BV, has incorporated a new wholly-owned entity in France named Arrow Pharma Production SAS. The new subsidiary is established with an authorized capital of 100,000 EUR, divided into 100,000 shares of 1 EUR each. This strategic move is specifically aimed at expanding the company's manufacturing footprint for generic formulations within the French market. This development underscores Aurobindo's commitment to strengthening its localized production capabilities in the European region.
Key Highlights
Incorporation of Arrow Pharma Production SAS in France as a 100% step-down subsidiary.
Authorized share capital of 100,000 EUR subscribed entirely in cash.
Entity focused on the manufacturing of generic formulations to serve the French market.
The incorporation was completed on May 21, 2026, with no regulatory approvals required.
👀 What to Watch
Investors should view this as a positive step toward deepening market penetration in Europe. Monitor future capital expenditure announcements related to this new manufacturing facility for long-term growth implications.
Aurobindo Pharma Q4FY26 Revenue up 5.6% YoY to ₹8,853 Cr; Europe Business Surges 30%
Aurobindo Pharma reported a steady Q4FY26 with consolidated revenue growing 5.6% YoY to ₹8,853 crore, supported by a robust 30.2% growth in the Europe formulations segment and a 12.9% rise in API sales. Net profit for the quarter stood at ₹921 crore, up 2% YoY, despite a 13% decline in US revenue caused by seasonality and lower transient product sales. The company is aggressively pivoting towards high-value segments, evidenced by an expanded CDMO partnership with MSD and a planned $150-175 million Capex for a new biologics facility.
Key Highlights
Consolidated Revenue increased 5.6% YoY to ₹8,853 Cr, while EBITDA margin remained stable at 20.3%.
Europe business delivered strong performance with 30.2% YoY growth, reaching ₹2,795 Cr in Q4FY26.
US Formulations revenue declined 13% YoY to ₹3,543 Cr, though the company launched 12 new products during the quarter.
Announced a $150-175 million Capex for a new greenfield Drug Substance facility (Unit 2) to support the expanded MSD partnership.
Maintains a strong balance sheet with a net cash position of approximately $317 million as of March 31, 2026.
👀 What to Watch
Investors should focus on the company's transition into complex generics and biosimilars, which are expected to drive margins higher by 2028-2030. The expansion of the MSD partnership provides high visibility for the TheraNym CDMO business, making the stock attractive for long-term portfolios despite short-term US market volatility.
Aurobindo Pharma Q4 Revenue up 5.6% to ₹8,853 Cr; Europe Business Crosses €1bn Milestone
Aurobindo Pharma reported a steady 5.6% YoY revenue growth in Q4 FY26, reaching ₹8,853 Cr, while net profit grew marginally by 2% to ₹921 Cr. The European segment was the standout performer, growing 30.2% YoY in Q4 and surpassing the €1 billion revenue milestone for the full year. However, the US market faced headwinds with a 13% YoY revenue decline due to lower transient sales. Despite a 104 bps contraction in EBITDA margins to 20.3%, the company maintained a strong net cash position after completing the $317 million acquisition of Khandelwal Laboratories' non-oncology business.
Key Highlights
Consolidated revenue for Q4 FY26 grew 5.6% YoY to ₹8,853 Cr, while FY26 revenue rose 6.1% to ₹33,653 Cr.
European business crossed the €1 billion annual revenue milestone, with Q4 revenues up 30.2% YoY to ₹2,795 Cr.
US formulation revenue declined by 13% YoY to ₹3,543 Cr, now representing 40% of total consolidated revenue.
EBITDA margin (before R&D) contracted by 182 bps YoY to 24.5% during the quarter.
Completed the acquisition of Khandelwal Laboratories (non-oncology) business for USD 317 million while maintaining a net cash position.
👀 What to Watch
Investors should monitor the recovery of the US business and the margin trajectory in upcoming quarters. While European growth is robust, the decline in the US market and margin compression warrant a 'Watch' approach to see if operational efficiencies improve.
Aurobindo Pharma FY26 Standalone PAT Jumps 38% to ₹24,148 Mn; ₹8,000 Mn Buyback Completed
Aurobindo Pharma reported a strong standalone performance for FY26, with Net Profit rising 38.2% YoY to ₹24,148 million despite a modest 2.2% growth in revenue to ₹1,11,717.2 million. The company successfully executed a share buyback of 5.42 million shares at ₹1,475 per share, returning ₹8,000 million to shareholders in May 2026. Cash flow from operations remained robust at ₹29,330.2 million, a significant increase from the previous year's ₹16,457.9 million. An exceptional charge of ₹173.8 million was recognized due to the impact of new Indian Labour Codes on employee benefit liabilities.
Key Highlights
Standalone Net Profit for FY26 increased to ₹24,148 million from ₹17,467.9 million in FY25.
Total Revenue from operations for the full year stood at ₹1,11,717.2 million, up from ₹1,09,333.0 million.
Completed buyback of 5,423,728 equity shares at ₹1,475 per share for a total consideration of ₹8,000 million.
Net cash flow from operating activities surged to ₹29,330.2 million compared to ₹16,457.9 million in the prior year.
Exceptional item of ₹173.8 million booked in Q3/FY26 related to gratuity and leave liability under new Labour Codes.
👀 What to Watch
Investors should view the strong profit growth and successful buyback as signs of healthy operational efficiency and capital allocation. The significant improvement in operating cash flows provides a strong cushion for future expansions.
Aurobindo Pharma Subsidiary Receives CDSCO Approval for Bevqolva Biosimilar
Aurobindo Pharma's wholly owned subsidiary, CuraTeQ Biologics, has received marketing authorization from the CDSCO for Bevqolva, a bevacizumab biosimilar. The drug is indicated for treating metastatic carcinoma of the colon or rectum, marking a significant entry into the oncology biosimilars market. The approval covers two vial presentations, 100 mg/4mL and 400 mg/16 mL, to be manufactured at the company's Hyderabad facility. This regulatory milestone strengthens Aurobindo's biologics portfolio and its long-term growth prospects in high-value therapeutic areas.
Key Highlights
CuraTeQ Biologics received CDSCO Marketing Authorisation (Form CT 23) for Bevqolva (Bevacizumab Biosimilar).
The biosimilar is indicated for the treatment of metastatic carcinoma of the colon or rectum.
Approval includes two specific vial presentations: 100 mg/4mL and 400 mg/16 mL.
Manufacturing and marketing will be conducted from CuraTeQ’s dedicated facility in Hyderabad.
👀 What to Watch
Investors should view this as a positive development in Aurobindo's shift toward complex biologics. Monitor the commercial rollout and potential for future international regulatory filings for this biosimilar.
Aurobindo Pharma Subsidiary Receives CDSCO Approval for Bevqolva Biosimilar
Aurobindo Pharma's wholly owned subsidiary, CuraTeQ Biologics, has received marketing authorization (Form CT 23) from the CDSCO for Bevqolva, a bevacizumab biosimilar. The drug is indicated for the treatment of metastatic carcinoma of the colon or rectum, marking a significant entry into the oncology biosimilar market. The authorization covers two presentations, 100 mg/4mL and 400 mg/16 mL vials, to be manufactured at the company's Hyderabad facility. This approval strengthens Aurobindo's specialty pipeline and its presence in the high-growth biologics segment.
Key Highlights
CuraTeQ Biologics granted CDSCO Marketing Authorisation for Bevqolva (Bevacizumab Biosimilar)
Indicated for metastatic carcinoma of the colon or rectum (colorectal cancer)
Approved for manufacture and marketing in 100 mg/4mL and 400 mg/16 mL vial presentations
Production to be localized at CuraTeQ’s dedicated facility in Hyderabad, India
👀 What to Watch
Investors should monitor the commercial rollout of Bevqolva and its impact on the company's domestic oncology revenue. This approval validates Aurobindo's R&D capabilities in the complex biosimilars space, which is a key long-term growth driver.
Aurobindo Pharma Completes ₹800 Cr Buyback; Extinguishes 54.23 Lakh Shares at ₹1,475/share
Aurobindo Pharma has successfully concluded its share buyback program, extinguishing 54,23,728 equity shares as of May 15, 2026. The company repurchased these shares at a price of ₹1,475 per share via the tender offer route, representing a total capital return of ₹800 crore. As a result, the total equity base has been reduced from 58.08 crore shares to 57.54 crore shares. The promoter group's shareholding has marginally increased from 51.82% to 51.88% following the extinguishment.
Key Highlights
Extinguished 54,23,728 fully paid-up equity shares of ₹1 face value each.
Shares were bought back at a premium price of ₹1,475 per share for a total of ₹800 crore.
Total issued share capital reduced from 58,08,01,623 to 57,53,77,895 equity shares.
Promoter and Promoter Group holding increased slightly to 51.88% from 51.82%.
The buyback was executed through the tender offer route in compliance with SEBI regulations.
👀 What to Watch
The reduction in the total number of shares is expected to be EPS-accretive, which is a positive signal for long-term shareholders. Investors should note the management's willingness to return surplus cash to shareholders at a significant premium to the face value.
Aurobindo Pharma Unit-VII Receives VAI Status from US FDA, Closing Inspection
Aurobindo Pharma's Unit-VII, a major oral solid dosage manufacturing facility in Jedcherla, has received an Establishment Inspection Report (EIR) from the US FDA. The facility was previously issued a Form 483 with 9 observations following an inspection conducted between January 28 and February 10, 2026. The US FDA has now classified the unit as Voluntary Action Indicated (VAI), which signifies that the inspection is officially closed. This is a positive development as it removes regulatory uncertainty and allows the facility to continue operations and seek new product approvals.
Key Highlights
Unit-VII (Jedcherla) classified as Voluntary Action Indicated (VAI) by US FDA
The US FDA inspection was conducted from January 28 to February 10, 2026
The facility had previously received a Form 483 with 9 observations
Receipt of the Establishment Inspection Report (EIR) marks the formal closure of the inspection
👀 What to Watch
Investors should view this as a positive resolution to a previous regulatory overhang, clearing the path for future product approvals from this unit. Maintain a positive outlook on the stock as regulatory risks for this specific facility have subsided.
